PandemieGrippaleV1, PascalFrancis, Corpus, bibRecord, 000E55

Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus

Identifieur interne : 000E55 ( PascalFrancis/Corpus ); précédent : 000E54; suivant : 000E56

Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus

Auteurs : Peter Pushko ; Thomas Kort ; Margret Nathan ; Melissa B. Pearce ; Gale Smith ; Terrence M. Tumpey

Source :

Vaccine [ 0264-410X ] ; 2010.

RBID : Pascal:11-0117519

Descripteurs français

Pascal (Inist)
- Virus grippal A, Virus recombinant, Particule type viral, Vaccin, Immunoprotection, Furet, Grippe.

English descriptors

KwdEn :
- Ferret, Immunoprotection, Influenza, Influenza A virus, Recombinant virus, Vaccine, Virus like particle.

Abstract

The pandemic virus of 2009 (2009 H1N1) continues to cause illness worldwide, especially in younger age groups. The widespread H1N1 virus infection further emphasizes the need for vaccine strategies that are effective against emerging pandemic viruses and are not dependent on the limitations of traditional egg-based technology. This report describes a recombinant influenza virus-like particle (VLP) vaccine consisting of hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins of influenza A/California/04/2009 (H1N1) virus. Influenza H1N1 VLPs with a diameter of approximately 120 nm were released into the culture medium from Sf9 insect cells infected with recombinant baculovirus coexpressing HA, NA, and M1 proteins. Purified recombinant H1N1 VLPs morphologically resembled influenza virions and exhibited biological characteristics of influenza virus, including HA and NA activities. In the ferret challenge model, 2009 influenza H1 N1 VLPs elicited high-titer serum hemagglutination inhibition (HI) antibodies specific for the 2009 H1N1 virus and inhibited replication of the influenza virus in the upper and lower respiratory tract tissues following A/Mexico/4482/09 (H1N1) virus challenge. Moreover, a single 15 μg dose of H1N1 VLPs resulted in complete virus clearance in the ferret lung. These results provide support for the use of recombinant influenza VLP vaccine as an effective strategy against pandemic H1N1 virus.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 28`
A06				`@2 30`
A08	`01`	`1`	`ENG`	`@1 Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus`
A11	`01`	`1`		`@1 PUSHKO (Peter)`
A11	`02`	`1`		`@1 KORT (Thomas)`
A11	`03`	`1`		`@1 NATHAN (Margret)`
A11	`04`	`1`		`@1 PEARCE (Melissa B.)`
A11	`05`	`1`		`@1 SMITH (Gale)`
A11	`06`	`1`		`@1 TUMPEY (Terrence M.)`
A14	`01`			`@1 Novavax, Inc., 9920 Belward Campus Drive @2 Rockville, MD 20850 @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut.`
A14	`02`			`@1 Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E. @2 Atlanta, GA 30333 @3 USA @Z 4 aut. @Z 6 aut.`
A20				`@1 4771-4776`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000191707790110`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 44 ref.`
A47	`01`	`1`		`@0 11-0117519`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The pandemic virus of 2009 (2009 H1N1) continues to cause illness worldwide, especially in younger age groups. The widespread H1N1 virus infection further emphasizes the need for vaccine strategies that are effective against emerging pandemic viruses and are not dependent on the limitations of traditional egg-based technology. This report describes a recombinant influenza virus-like particle (VLP) vaccine consisting of hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins of influenza A/California/04/2009 (H1N1) virus. Influenza H1N1 VLPs with a diameter of approximately 120 nm were released into the culture medium from Sf9 insect cells infected with recombinant baculovirus coexpressing HA, NA, and M1 proteins. Purified recombinant H1N1 VLPs morphologically resembled influenza virions and exhibited biological characteristics of influenza virus, including HA and NA activities. In the ferret challenge model, 2009 influenza H1 N1 VLPs elicited high-titer serum hemagglutination inhibition (HI) antibodies specific for the 2009 H1N1 virus and inhibited replication of the influenza virus in the upper and lower respiratory tract tissues following A/Mexico/4482/09 (H1N1) virus challenge. Moreover, a single 15 μg dose of H1N1 VLPs resulted in complete virus clearance in the ferret lung. These results provide support for the use of recombinant influenza VLP vaccine as an effective strategy against pandemic H1N1 virus.
C02	`01`	`X`		`@0 002A05F04`
C02	`02`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Virus grippal A @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Influenza A virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Influenza A virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Virus recombinant @5 05`
C03	`02`	`X`	`ENG`	`@0 Recombinant virus @5 05`
C03	`02`	`X`	`SPA`	`@0 Virus recombinante @5 05`
C03	`03`	`X`	`FRE`	`@0 Particule type viral @5 06`
C03	`03`	`X`	`ENG`	`@0 Virus like particle @5 06`
C03	`03`	`X`	`SPA`	`@0 Partícula tipo vírico @5 06`
C03	`04`	`X`	`FRE`	`@0 Vaccin @5 07`
C03	`04`	`X`	`ENG`	`@0 Vaccine @5 07`
C03	`04`	`X`	`SPA`	`@0 Vacuna @5 07`
C03	`05`	`X`	`FRE`	`@0 Immunoprotection @5 08`
C03	`05`	`X`	`ENG`	`@0 Immunoprotection @5 08`
C03	`05`	`X`	`SPA`	`@0 Inmunoprotección @5 08`
C03	`06`	`X`	`FRE`	`@0 Furet @5 09`
C03	`06`	`X`	`ENG`	`@0 Ferret @5 09`
C03	`06`	`X`	`SPA`	`@0 Hurón @5 09`
C03	`07`	`X`	`FRE`	`@0 Grippe @5 14`
C03	`07`	`X`	`ENG`	`@0 Influenza @5 14`
C03	`07`	`X`	`SPA`	`@0 Gripe @5 14`
C07	`01`	`X`	`FRE`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`ENG`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`SPA`	`@0 Influenzavirus A @2 NW`
C07	`02`	`X`	`FRE`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Orthomyxoviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Fissipedia @2 NS`
C07	`04`	`X`	`ENG`	`@0 Fissipedia @2 NS`
C07	`04`	`X`	`SPA`	`@0 Fissipedia @2 NS`
C07	`05`	`X`	`FRE`	`@0 Carnivora @2 NS`
C07	`05`	`X`	`ENG`	`@0 Carnivora @2 NS`
C07	`05`	`X`	`SPA`	`@0 Carnivora @2 NS`
C07	`06`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`06`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`06`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`07`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`07`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`07`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`08`	`X`	`FRE`	`@0 Virose`
C07	`08`	`X`	`ENG`	`@0 Viral disease`
C07	`08`	`X`	`SPA`	`@0 Virosis`
C07	`09`	`X`	`FRE`	`@0 Infection`
C07	`09`	`X`	`ENG`	`@0 Infection`
C07	`09`	`X`	`SPA`	`@0 Infección`
N21				`@1 073`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0117519 INIST
ET :	Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus
AU :	PUSHKO (Peter); KORT (Thomas); NATHAN (Margret); PEARCE (Melissa B.); SMITH (Gale); TUMPEY (Terrence M.)
AF :	Novavax, Inc., 9920 Belward Campus Drive/Rockville, MD 20850/Etats-Unis (1 aut., 2 aut., 3 aut., 5 aut.); Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E./Atlanta, GA 30333/Etats-Unis (4 aut., 6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2010; Vol. 28; No. 30; Pp. 4771-4776; Bibl. 44 ref.
LA :	Anglais
EA :	The pandemic virus of 2009 (2009 H1N1) continues to cause illness worldwide, especially in younger age groups. The widespread H1N1 virus infection further emphasizes the need for vaccine strategies that are effective against emerging pandemic viruses and are not dependent on the limitations of traditional egg-based technology. This report describes a recombinant influenza virus-like particle (VLP) vaccine consisting of hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins of influenza A/California/04/2009 (H1N1) virus. Influenza H1N1 VLPs with a diameter of approximately 120 nm were released into the culture medium from Sf9 insect cells infected with recombinant baculovirus coexpressing HA, NA, and M1 proteins. Purified recombinant H1N1 VLPs morphologically resembled influenza virions and exhibited biological characteristics of influenza virus, including HA and NA activities. In the ferret challenge model, 2009 influenza H1 N1 VLPs elicited high-titer serum hemagglutination inhibition (HI) antibodies specific for the 2009 H1N1 virus and inhibited replication of the influenza virus in the upper and lower respiratory tract tissues following A/Mexico/4482/09 (H1N1) virus challenge. Moreover, a single 15 μg dose of H1N1 VLPs resulted in complete virus clearance in the ferret lung. These results provide support for the use of recombinant influenza VLP vaccine as an effective strategy against pandemic H1N1 virus.
CC :	002A05F04; 002A05C10
FD :	Virus grippal A; Virus recombinant; Particule type viral; Vaccin; Immunoprotection; Furet; Grippe
FG :	Influenzavirus A; Orthomyxoviridae; Virus; Fissipedia; Carnivora; Mammalia; Vertebrata; Virose; Infection
ED :	Influenza A virus; Recombinant virus; Virus like particle; Vaccine; Immunoprotection; Ferret; Influenza
EG :	Influenzavirus A; Orthomyxoviridae; Virus; Fissipedia; Carnivora; Mammalia; Vertebrata; Viral disease; Infection
SD :	Influenza A virus; Virus recombinante; Partícula tipo vírico; Vacuna; Inmunoprotección; Hurón; Gripe
LO :	INIST-20289.354000191707790110
ID :	11-0117519

Links to Exploration step

Pascal:11-0117519

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus</title>
<author><name sortKey="Pushko, Peter" sort="Pushko, Peter" uniqKey="Pushko P" first="Peter" last="Pushko">Peter Pushko</name>
<affiliation><inist:fA14 i1="01"><s1>Novavax, Inc., 9920 Belward Campus Drive</s1>
<s2>Rockville, MD 20850</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kort, Thomas" sort="Kort, Thomas" uniqKey="Kort T" first="Thomas" last="Kort">Thomas Kort</name>
<affiliation><inist:fA14 i1="01"><s1>Novavax, Inc., 9920 Belward Campus Drive</s1>
<s2>Rockville, MD 20850</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nathan, Margret" sort="Nathan, Margret" uniqKey="Nathan M" first="Margret" last="Nathan">Margret Nathan</name>
<affiliation><inist:fA14 i1="01"><s1>Novavax, Inc., 9920 Belward Campus Drive</s1>
<s2>Rockville, MD 20850</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pearce, Melissa B" sort="Pearce, Melissa B" uniqKey="Pearce M" first="Melissa B." last="Pearce">Melissa B. Pearce</name>
<affiliation><inist:fA14 i1="02"><s1>Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E.</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Smith, Gale" sort="Smith, Gale" uniqKey="Smith G" first="Gale" last="Smith">Gale Smith</name>
<affiliation><inist:fA14 i1="01"><s1>Novavax, Inc., 9920 Belward Campus Drive</s1>
<s2>Rockville, MD 20850</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tumpey, Terrence M" sort="Tumpey, Terrence M" uniqKey="Tumpey T" first="Terrence M." last="Tumpey">Terrence M. Tumpey</name>
<affiliation><inist:fA14 i1="02"><s1>Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E.</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0117519</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 11-0117519 INIST</idno>
<idno type="RBID">Pascal:11-0117519</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus</title>
<author><name sortKey="Pushko, Peter" sort="Pushko, Peter" uniqKey="Pushko P" first="Peter" last="Pushko">Peter Pushko</name>
<affiliation><inist:fA14 i1="01"><s1>Novavax, Inc., 9920 Belward Campus Drive</s1>
<s2>Rockville, MD 20850</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kort, Thomas" sort="Kort, Thomas" uniqKey="Kort T" first="Thomas" last="Kort">Thomas Kort</name>
<affiliation><inist:fA14 i1="01"><s1>Novavax, Inc., 9920 Belward Campus Drive</s1>
<s2>Rockville, MD 20850</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nathan, Margret" sort="Nathan, Margret" uniqKey="Nathan M" first="Margret" last="Nathan">Margret Nathan</name>
<affiliation><inist:fA14 i1="01"><s1>Novavax, Inc., 9920 Belward Campus Drive</s1>
<s2>Rockville, MD 20850</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pearce, Melissa B" sort="Pearce, Melissa B" uniqKey="Pearce M" first="Melissa B." last="Pearce">Melissa B. Pearce</name>
<affiliation><inist:fA14 i1="02"><s1>Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E.</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Smith, Gale" sort="Smith, Gale" uniqKey="Smith G" first="Gale" last="Smith">Gale Smith</name>
<affiliation><inist:fA14 i1="01"><s1>Novavax, Inc., 9920 Belward Campus Drive</s1>
<s2>Rockville, MD 20850</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tumpey, Terrence M" sort="Tumpey, Terrence M" uniqKey="Tumpey T" first="Terrence M." last="Tumpey">Terrence M. Tumpey</name>
<affiliation><inist:fA14 i1="02"><s1>Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E.</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ferret</term>
<term>Immunoprotection</term>
<term>Influenza</term>
<term>Influenza A virus</term>
<term>Recombinant virus</term>
<term>Vaccine</term>
<term>Virus like particle</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term>
<term>Virus recombinant</term>
<term>Particule type viral</term>
<term>Vaccin</term>
<term>Immunoprotection</term>
<term>Furet</term>
<term>Grippe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pandemic virus of 2009 (2009 H1N1) continues to cause illness worldwide, especially in younger age groups. The widespread H1N1 virus infection further emphasizes the need for vaccine strategies that are effective against emerging pandemic viruses and are not dependent on the limitations of traditional egg-based technology. This report describes a recombinant influenza virus-like particle (VLP) vaccine consisting of hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins of influenza A/California/04/2009 (H1N1) virus. Influenza H1N1 VLPs with a diameter of approximately 120 nm were released into the culture medium from Sf9 insect cells infected with recombinant baculovirus coexpressing HA, NA, and M1 proteins. Purified recombinant H1N1 VLPs morphologically resembled influenza virions and exhibited biological characteristics of influenza virus, including HA and NA activities. In the ferret challenge model, 2009 influenza H1 N1 VLPs elicited high-titer serum hemagglutination inhibition (HI) antibodies specific for the 2009 H1N1 virus and inhibited replication of the influenza virus in the upper and lower respiratory tract tissues following A/Mexico/4482/09 (H1N1) virus challenge. Moreover, a single 15 μg dose of H1N1 VLPs resulted in complete virus clearance in the ferret lung. These results provide support for the use of recombinant influenza VLP vaccine as an effective strategy against pandemic H1N1 virus.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>28</s2>
</fA05>
<fA06><s2>30</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PUSHKO (Peter)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KORT (Thomas)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>NATHAN (Margret)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PEARCE (Melissa B.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SMITH (Gale)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TUMPEY (Terrence M.)</s1>
</fA11>
<fA14 i1="01"><s1>Novavax, Inc., 9920 Belward Campus Drive</s1>
<s2>Rockville, MD 20850</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E.</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>4771-4776</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000191707790110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>44 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0117519</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The pandemic virus of 2009 (2009 H1N1) continues to cause illness worldwide, especially in younger age groups. The widespread H1N1 virus infection further emphasizes the need for vaccine strategies that are effective against emerging pandemic viruses and are not dependent on the limitations of traditional egg-based technology. This report describes a recombinant influenza virus-like particle (VLP) vaccine consisting of hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins of influenza A/California/04/2009 (H1N1) virus. Influenza H1N1 VLPs with a diameter of approximately 120 nm were released into the culture medium from Sf9 insect cells infected with recombinant baculovirus coexpressing HA, NA, and M1 proteins. Purified recombinant H1N1 VLPs morphologically resembled influenza virions and exhibited biological characteristics of influenza virus, including HA and NA activities. In the ferret challenge model, 2009 influenza H1 N1 VLPs elicited high-titer serum hemagglutination inhibition (HI) antibodies specific for the 2009 H1N1 virus and inhibited replication of the influenza virus in the upper and lower respiratory tract tissues following A/Mexico/4482/09 (H1N1) virus challenge. Moreover, a single 15 μg dose of H1N1 VLPs resulted in complete virus clearance in the ferret lung. These results provide support for the use of recombinant influenza VLP vaccine as an effective strategy against pandemic H1N1 virus.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus grippal A</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus recombinant</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Recombinant virus</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Virus recombinante</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Particule type viral</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Virus like particle</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Partícula tipo vírico</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Immunoprotection</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immunoprotection</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inmunoprotección</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Furet</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Ferret</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hurón</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Grippe</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Influenza</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Gripe</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Fissipedia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Fissipedia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Fissipedia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Carnivora</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Carnivora</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Carnivora</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>073</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0117519 INIST</NO>
<ET>Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus</ET>
<AU>PUSHKO (Peter); KORT (Thomas); NATHAN (Margret); PEARCE (Melissa B.); SMITH (Gale); TUMPEY (Terrence M.)</AU>
<AF>Novavax, Inc., 9920 Belward Campus Drive/Rockville, MD 20850/Etats-Unis (1 aut., 2 aut., 3 aut., 5 aut.); Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road N.E./Atlanta, GA 30333/Etats-Unis (4 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2010; Vol. 28; No. 30; Pp. 4771-4776; Bibl. 44 ref.</SO>
<LA>Anglais</LA>
<EA>The pandemic virus of 2009 (2009 H1N1) continues to cause illness worldwide, especially in younger age groups. The widespread H1N1 virus infection further emphasizes the need for vaccine strategies that are effective against emerging pandemic viruses and are not dependent on the limitations of traditional egg-based technology. This report describes a recombinant influenza virus-like particle (VLP) vaccine consisting of hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins of influenza A/California/04/2009 (H1N1) virus. Influenza H1N1 VLPs with a diameter of approximately 120 nm were released into the culture medium from Sf9 insect cells infected with recombinant baculovirus coexpressing HA, NA, and M1 proteins. Purified recombinant H1N1 VLPs morphologically resembled influenza virions and exhibited biological characteristics of influenza virus, including HA and NA activities. In the ferret challenge model, 2009 influenza H1 N1 VLPs elicited high-titer serum hemagglutination inhibition (HI) antibodies specific for the 2009 H1N1 virus and inhibited replication of the influenza virus in the upper and lower respiratory tract tissues following A/Mexico/4482/09 (H1N1) virus challenge. Moreover, a single 15 μg dose of H1N1 VLPs resulted in complete virus clearance in the ferret lung. These results provide support for the use of recombinant influenza VLP vaccine as an effective strategy against pandemic H1N1 virus.</EA>
<CC>002A05F04; 002A05C10</CC>
<FD>Virus grippal A; Virus recombinant; Particule type viral; Vaccin; Immunoprotection; Furet; Grippe</FD>
<FG>Influenzavirus A; Orthomyxoviridae; Virus; Fissipedia; Carnivora; Mammalia; Vertebrata; Virose; Infection</FG>
<ED>Influenza A virus; Recombinant virus; Virus like particle; Vaccine; Immunoprotection; Ferret; Influenza</ED>
<EG>Influenzavirus A; Orthomyxoviridae; Virus; Fissipedia; Carnivora; Mammalia; Vertebrata; Viral disease; Infection</EG>
<SD>Influenza A virus; Virus recombinante; Partícula tipo vírico; Vacuna; Inmunoprotección; Hurón; Gripe</SD>
<LO>INIST-20289.354000191707790110</LO>
<ID>11-0117519</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E55 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000E55 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0117519
   |texte=   Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus

Recombinant H1 N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri